X

Trial Profile

A Phase I/II Trial of Intracerebroventricular 177Lu DTPA Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 19 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omburtamab-Lu-177 (Primary)
Indications Cancer metastases; CNS cancer; Meningeal carcinomatosis
Focus Adverse reactions
Sponsors Y-mAbs Therapeutics

Most Recent Events

12 Jul 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
07 Jul 2022 Planned initiation date changed from 30 Jun 2022 to 31 Aug 2022.
28 Apr 2022 Status changed from recruiting to not yet recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com